Revive Therapeutics Ltd.
RVV
CNSX
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 944.90K | 1.08M | 953.70K | 1.65M | 1.70M |
| Depreciation & Amortization | 0.00 | 0.00 | 100.00 | 200.00 | 300.00 |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 944.90K | 1.18M | 1.11M | 2.15M | 2.52M |
| Operating Income | -944.90K | -1.18M | -1.11M | -2.15M | -2.52M |
| Income Before Tax | -7.80M | -7.95M | -2.90M | -3.88M | -4.19M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -7.80 | -7.95 | -2.90 | -3.88 | -4.19 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -7.80M | -7.95M | -2.90M | -3.88M | -4.19M |
| EBIT | -944.90K | -1.18M | -1.11M | -2.15M | -2.52M |
| EBITDA | -944.90K | -1.18M | -1.11M | -2.15M | -2.52M |
| EPS Basic | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | -0.02 | -0.02 | -0.01 | -0.01 | -0.01 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 1.69B | 1.68B | 1.67B | 1.64B | 1.58B |
| Average Diluted Shares Outstanding | 1.69B | 1.68B | 1.67B | 1.64B | 1.58B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |